Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Tampa, Florida

CNS medication trials in Tampa, FL

54 CNS medication studies are recruiting participants at sites in Tampa as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Tampa at a glance

Depression studies recruiting in Tampa

Basic details from each study's public record (the 30 most recently updated of 54). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study sites
    Cenexel Tampa · Interventional Psychiatry of Tampa Bay
    Registry record
    NCT07226661 · updated
  2. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    K2 Medical Research Tampa
    Registry record
    NCT06793397 · updated
  3. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    University of South Florida, Department of Psychiatry and Behavioral Neuroscience
    Registry record
    NCT07002034 · updated
  4. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    K2 Medical Research (Tampa)
    Registry record
    NCT07592689 · updated
  5. ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Study site
    IPTB Clinical Research
    Registry record
    NCT07284667 · updated
  6. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    K2 Medical Research - Tampa
    Registry record
    NCT07412756 · updated
  7. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Interventional Psychiatry of Tampa Bay
    Registry record
    NCT05850689 · updated
  8. Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    Interventional Psychiatry of Tampa Bay · Psych Me Medical Research Inc
    Registry record
    NCT06559306 · updated
  9. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    IPTB Clinical Research
    Registry record
    NCT07573176 · updated
  10. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated
  11. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Tampa, FL on ClinicalTrials.gov.

Schizophrenia studies recruiting in Tampa

  1. Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

    • Phase 3
    • Ages 18 to 55
    • All sexes
    Sponsor
    Minerva Neurosciences
    Study site
    ForCare Clinical Research
    Registry record
    NCT07565428 · updated
  2. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  3. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    University of South Florida
    Registry record
    NCT06540833 · updated
  4. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study sites
    Guardian Angel Research · Interventional Psychiatry of Tampa Bay
    Registry record
    NCT06585787 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Tampa, FL on ClinicalTrials.gov.

ADHD studies recruiting in Tampa

  1. A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Alkermes, Inc.
    Study site
    Alkermes Investigational Site
    Registry record
    NCT07755410 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Tampa, FL on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Tampa

  1. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Moffit Cancer Center ( Site 5026)
    Registry record
    NCT07216703 · updated
  2. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  3. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    USF Parkinsons Disease and Movement Disorders Center
    Registry record
    NCT07174310 · updated
  4. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    USF Parkinson's & Movement Disorders Clinic
    Registry record
    NCT06680830 · updated
  5. A Study of Buntanetap in Participants With PD

    • Phase 2/3
    • Ages 40 to 85
    • All sexes
    Sponsor
    Annovis Bio Inc.
    Study site
    University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
    Registry record
    NCT07284784 · updated
  6. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Study site
    USF Parkinson's Disease and Movement Disorders Center (Site #206)
    Registry record
    NCT07432958 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Tampa, FL on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Tampa

  1. A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Study site
    University of South Florida Department of Neurology - MS Division
    Registry record
    NCT07299019 · updated
  2. A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Study site
    University of South Florida Department of Neurology - MS Division
    Registry record
    NCT07067463 · updated
  3. A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Sundance Biosciences, Inc.
    Study site
    Local Institution - Site 103
    Registry record
    NCT07840326 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Tampa, FL on ClinicalTrials.gov.

Epilepsy studies recruiting in Tampa

  1. A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

    • Phase 2/3
    • Ages 10 and older
    • All sexes
    Sponsor
    Jazz Pharmaceuticals
    Study site
    Pediatric Epilepsy & Neurology Specialists
    Registry record
    NCT07723963 · updated
  2. Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

    • Phase 3
    • Ages 4 to 55
    • All sexes
    Sponsor
    SK Life Science, Inc.
    Study site
    Pediatric Epilepsy and Neurology Specialists
    Registry record
    NCT05219617 · updated
  3. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    University of South Florida
    Registry record
    NCT05667142 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Tampa, FL on ClinicalTrials.gov.

Migraine studies recruiting in Tampa

  1. Study of EVO756 in Adults With Migraine

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Evommune, Inc.
    Study site
    Vantage Clinical Trials
    Registry record
    NCT07616128 · updated
  2. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Cenexel Tampa FL
    Registry record
    NCT07816367 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Tampa, FL on ClinicalTrials.gov.

Ask about studies near Tampa

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call